Gold Sponsor
Attovia Therapeutics: Translating cutting-edge innovation into breakthrough therapeutics
Attovia Therapeutics is a clinical-stage biopharma company developing transformative therapies for patients suffering from immune-mediated diseases, with a key focus on chronic pruritus. Driven by science and a deep commitment to patients, Attovia discovers and develops novel biologics that target the root causes of itch.
The company’s lead programs target IL-31, a cytokine increasingly recognized not only as an inflammatory signal but also as a neuroinflammatory driver of itch. This dual role makes IL-31 a compelling target across a range of indications, including chronic pruritus of unknown origin, atopic dermatitis, and other immune-mediated skin conditions. Attovia’s first clinical program, ATTO-1310, seeks to provide rapid, deep, and durable relief of itch through IL-31 inhibition for patients suffering from chronic pruritus, in a convenient subcutaneous formulation.
Attovia’s goal is to help patients by translating foundational immunology into clinically meaningful therapies. Leveraging their proprietary protein engineering platform, the team works with internationally recognized KOLs to build the next generation of biologic therapies to help patients in need.
« Go Back